This bill would change Medicare rules so patients and other affected parties have a formal review process when a national coverage determination denies drug coverage. It targets adverse coverage decisions under title XVIII of the Social Security Act, which governs Medicare. The main effect would be to give beneficiaries, providers, and drug plans a clearer path to challenge or revisit decisions that block coverage for certain medicines. The bill was introduced in the House and sent to the Ways and Means Committee and the Energy and Commerce Committee for further consideration.
What This Bill Does
- Amends title XVIII of the Social Security Act, which governs Medicare.
- Creates a review process for adverse national coverage determinations.
- Focuses specifically on drug coverage under the Medicare program.
- Applies to federal coverage decisions that can affect beneficiaries nationwide.
Who This Bill Affects
If you are enrolled in Medicare and take prescription drugs, this bill could give you an added route to challenge a national decision that limits coverage of a medication you rely on. That could mean better access and fewer abrupt coverage denials, though it may also mean Medicare takes longer to finalize some drug coverage determinations. For people not on Medicare, the direct effect is limited.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Medicare beneficiaries who rely on prescription drugs They would gain a formal way to contest coverage denials that can cut off access to needed medications. A review process can be especially valuable when a national decision affects many patients at once.
- Doctors and clinical advocates Clinicians may support added review because broad coverage denials can interfere with individualized treatment decisions. A structured appeal or review path can help ensure medical evidence is fully considered.
- Patient advocacy groups These groups often argue that national coverage rules should include stronger checks before restricting access to medications. They may see this as a fairness measure for people facing serious or chronic illnesses.
- Federal budget watchdogs They may worry that more review layers could slow down cost-control decisions and make it harder for Medicare to manage spending. If more drugs remain under reconsideration, program costs could rise.
- Medicare administrators Program officials may view the bill as adding procedural burdens to an already complex coverage system. A new review process can require more staff time, more documentation, and longer timelines.
- Taxpayer-focused fiscal conservatives They may argue that broader review rights could weaken national coverage standards meant to prevent spending on drugs that do not meet Medicare’s criteria. Their concern is that easier challenges to adverse decisions could reduce cost discipline.
Key Implications
-
““provide a review process””
This would give stakeholders a defined path to seek reconsideration of negative Medicare drug coverage decisions instead of relying only on existing administrative channels.
-
““adverse national coverage determinations””
The bill is aimed at broad federal coverage rulings that apply across Medicare, not just isolated case-by-case denials.
-
““with respect to drug coverage””
The change is focused on prescription and other drug coverage issues, so its effects would be concentrated on people using Medicare drug benefits.
-
““under the Medicare program””
The policy would operate inside Medicare, meaning the main people affected are beneficiaries, providers, and plans that participate in the program.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- HR 9418
- Congress
- 119th Congress
- Official title
- To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.
- Policy area
- Healthcare
- Latest action
- Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (June 24, 2026)
- Last updated
- June 25, 2026
Latest Status
June 24, 2026
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.